Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Non Randomized Clinical Trial of NIVOLUMAB/IPILIMUMAB Maintenance Following First-line Chemotherapy in Unresectable Locally Advanced or Metastatic Urothelial Cancer.

NCT05219435 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT05219435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Non Randomized Clinical Trial of NIVOLUMAB/IPILIMUMAB Maintenance Following First-line Chemotherapy in Unresectable Locally Advanced or Metastatic Urothelial Cancer.
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2022
Completion date
July 10, 2025
Enrollment
25 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial cancer